

SUPPORT FOR THE AMENDMENT

Support for the amendment to claim 3 is found in claim 1 as originally presented. No new matter would be added to this application by entry of this amendment.

Upon entry of this amendment claims 3, 7-10, 12, 16 and 18-31 will remain active in this application.

REQUEST FOR RECONSIDERATION

Applicants wish to thank examiner Coleman for indicating that the claims are free from prior art rejections.

The rejection of claims 3, 7-10, 12, 16, 24 and 31 under 35 U.S.C. §112 second paragraph is obviated in-part by appropriate amendment and traversed in-part.

Applicants have now amended claim 3 to include the definitions of groups “R<sup>12</sup>” and “s” as they appeared in claim 1 as originally presented.

As to claims 16, 24 and 31, applicants respectfully submit that the metes and bound of the term “pharmacologically active compounds” is clear to those of ordinary skill in the art, in the context of “A method for therapeutically treating the activity of progesterone.” Claims 16, 24 and 31 are dependant claims which depend from method claims for therapeutically treating the activity of progesterone. As such the metes and bound of the further administration of “pharmacologically active compounds” in the context of therapeutically treating the activity of progesterone is clear to those of ordinary skill in the art. Accordingly withdrawal of this ground of rejection is respectfully requested.

Application No. 10/611,785  
Reply to Office Action of August 26, 2004

The rejection of claims 3, 7,-10, 12, 18-23 and 25-30 under the judicially created doctrine of obviousness-type double patenting over claims 1-3 and 5-7 of U.S. 6,262,042 is obviated by the enclosed terminal disclaimer disclaiming the terminal portion of any patent issuing from the above-identified application which would extend beyond the full statutory term of U.S. 6,262,042 and require common ownership for the enforceable lifetime thereof. IN view of a the attached disclaimer, withdrawal of this ground of rejection is respectfully requested.

Applicants submit this application is now in condition for allowance and early notification of such action is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.  
Norman F. Oblon



---

Richard L. Chinn, Ph.D.  
Attorney of Record  
Registration No. 34,305

Customer Number  
**22850**

Tel: (703) 413-3000  
Fax: (703) 413 -2220  
(OSMMN 06/04)  
NFO/RLC/law